#Ivonescimab
LightNews LightNews
oncodaily.bsky.social
🚨New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer🚨

The HARMONi-2 study, a randomized phase 3 trial compared ivonescimab with pembrolizumab as first-line treatment for advanced PD-L1-positive non-small cell lung cancer (NSCLC). 💊
March 11, 2025 at 10:02 PM
oncodaily.bsky.social
Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC - Yüksel Ürün
@yukselurun.bsky.social

oncodaily.com/blog/252682

#Cancer #Medicine #Health #CancerResearch #LungCancer #LSCLC #CancerTreatment #Oncology #OncoDaily
Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC - OncoDaily
Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC / Anwen Xiong, Baogang Liu, Caicun Zhou, cancer, Jianhua Chen, Jun Yao, Junqiang Chen, Lei
oncodaily.com
March 8, 2025 at 8:04 PM
marcianobrito.bsky.social
O medicamento chinês Ivonescimab obteve desempenho superior ao estadunidense Keytruda em testes contra o câncer de pulmão. O resultado coloca em risco o domínio dos EUA no tratamento da doença e gera preocupação na indústria farmacêutica estadunidense, q pode perder sua posição de liderança no setor
Uma empresa chinesa pouco conhecida produziu um fármaco que derrotou o medicamento mais vendido no mundo
Em causa está um tratamento para o cancro do pulmão
cnnportugal.iol.pt
February 26, 2025 at 11:05 PM
acmoorephd.bsky.social
Ivonescimab, a novel bispecific Ab targeting PD-1 and VEGF, outperformed gold std pembro in a head to head comparison. It may unlock IO options for new patient pops, including EGFR+ post-TKI and SqNSCLC, plus other tumor types. #LCSM 👁️🫁

www.onclive.com/view/the-nov...
The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
www.onclive.com
December 28, 2024 at 4:32 PM
yourdigitalbrain.bsky.social
A new treatment could change the game for lung cancer patients,showing a staggering 34% reduction in death risk compared to existing therapies. What does this mean for the future of cancer care? 🫁✨
Ivonescimab reduces the risk of death from lung cancer by 34% compared to standard PD-1 inhibitor - Sinaptica
A molecule with two simultaneous targets Ivonescimab is not a conventional antibody. Developed by the Chinese biotechnology company Akeso Therapeutics and with
sinapti.ca
May 31, 2026 at 12:17 PM
adityabasu.bsky.social
New podcast episode! NexTechie BioFlux – The Brief: Pediatric AAV9 gene therapy approval, Hugo robotic autonomous vessel sealing & ivonescimab outperforming Keytruda in Phase 3.

Stream free on Patreon & Spotify: url.nextechie.in/EGRqiX

#Biotech #Podcast #HealthTech #MedTech
NexTechie BioFlux – The Brief: Pediatric Gene Therapy Breakthrough, Hugo Autonomous Vessel Sealing, and Ivonescimab Checkpoint Superiority | NexTechie
Welcome to NexTechie BioFlux. This week, biotechnology and medical technology achieved three foundational milestones that transform pediatri
url.nextechie.in
September 23, 2026 at 4:58 PM
byteseu.bsky.social
Ivonescimab is Now Being Studied in Europe in HARMONi-7 Trial – Lung Cancer Europe

https://www.byteseu.com/2181598/

Lung Cancer Europe shared a post on LinkedIn: “Ivonescimab was one of the most talked-about drugs in lung cancer at ASCO 2026, largely on the back of the HARMONi-6 results. The …
Ivonescimab is Now Being Studied in Europe in HARMONi-7 Trial - Lung Cancer Europe - Bytes Europe
Lung Cancer Europe shared a post on LinkedIn:
www.byteseu.com
July 10, 2026 at 12:39 AM
oncodaily.bsky.social
Read more about this study:
oncodaily.com/oncolibrary/...

#Cancer #CancerResearch #Medicine #Health #LungCancer #LSCM #NSCLC #Oncology #OncoDaily
New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer - OncoDaily
Read key results of HARMONi-2 in Lancet: Ivonescimab vs. pembrolizumab in PD-L1+ NSCLC. 49% lower risk of progression
oncodaily.com
March 11, 2025 at 10:02 PM
oncodaily.bsky.social
Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC - Yüksel Ürün

@yukselurun.bsky.social @erikahamilton9.bsky.social

oncodaily.com/voices/yukse...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ESMO #ESMO25 #ESMO2025
Yüksel Ürün: Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC - OncoDaily
Yüksel Ürün: Ivonescimab + Chemo Improves PFS in 1L sq-NSCLC / cancer, Erika Hamilton, ESMO, ESMO 2025, ESMO 2025 Congress, ESMO2025, ESMO25, OncoDaily,
oncodaily.com
October 19, 2025 at 9:44 PM
jinesh.bsky.social
Debating if I should include:
-PD-L1-CTLA-4 bispecfics and ivonescimab for emerging therapies
-role of ctDNA
-strategies for patients who have experience recurrence after neoadjuvant chemo-IO
November 24, 2024 at 8:28 PM
onclive.bsky.social
The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC #lcsm #oncology www.onclive.com/view/the-nov...
The Novel Bispecific Antibody Ivonescimab May be Poised to Change the SOC in NSCLC
Jonathan Wesley Riess, MD, MS, details the potential for ivonescimab in NSCLC after improving PFS vs pembrolizumab in the HARMONi-2 trial.
www.onclive.com
December 23, 2024 at 7:08 PM
oncodaily.bsky.social
Ivonescimab demonstrated a significant improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 49%, with benefits observed across PD-L1 expression subgroups and both squamous and non-squamous histologies.‍🔬
March 11, 2025 at 10:02 PM
fonteufficiale.bsky.social
🟠 Michelle Xia, scienziata cinese che ha fondato Akeso Biopharma nel 2012 con tre colleghi, ha sviluppato il farmaco sperimentale ivonescimab: potrebbe diventare il primo anticorpo monoclonale bispecifico cinese approvato negli Stati Uniti... [...]
buff.ly/d7VTRrL
Michelle Xia, la scienziata cinese che per la cura del cancro sfida i giganti biotech occidentali
Michelle Xia, scienziata cinese che ha fondato Akeso Biopharma nel 2012 con tre colleghi, ha sviluppato il farmaco sperimentale ivonescimab: potrebbe diventare il primo anticorpo monoclonale…
fonteufficiale.it
July 14, 2025 at 5:02 PM
endpts.com
Akeso and Summit's ivonescimab cut the risk of death 27% versus Keytruda in first-line lung cancer in a China-based trial.
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
Akeso/Summit's ivonescimab cut death risk 27% vs Merck's Keytruda in HARMONi-2 lung cancer trial; median survival 30.75 vs 22.57 months.
endpoints.news
September 14, 2026 at 6:00 PM
markfortner.bsky.social
Summit sells failed antibiotic to OpenAI-backed startup in $105M deal | #biotech #AI
Summit sells failed antibiotic to OpenAI-backed startup in $105M deal
Summit Therapeutics has cleared out an asset from its pre-ivonescimab history,
www.fiercebiotech.com
July 15, 2026 at 2:55 PM
onclive.bsky.social
Ivonescimab Shows Significant PFS Improvement Over Pembrolizumab in PD-L1+ NSCLC @mdanderson.bsky.social #lcsm #oncology
www.onclive.com/view/ivonesc...
Ivonescimab Shows Significant PFS Improvement Over Pembrolizumab in PD-L1+ NSCLC
Xiuning Le, MD, PhD, discusses data from the HARMONi-2 trial of ivonescimab vs pembrolizumab in PD-L1–positive NSCLC.
www.onclive.com
March 31, 2025 at 2:09 PM
cerebrodigital.net
El fármaco, también conocido como AK112 en China y como SMT112 fuera de ese mercado, fue desarrollado por la biofarmacéutica china Akeso , que licenció sus derechos para Estados Unidos, Canadá, Europa y Japón a Summit Therapeutics .
Ivonescimab, biespecífico PD-1/VEGF, logra 80% de respuesta objetiva en cáncer de mama triple negativo - Sinaptica
Qué encontró el ensayo Un ensayo clínico de fase 2 publicado en Nature Medicine muestra que ivonescimab, un anticuerpo biespecífico que bloquea a la vez las rut
sinapti.ca
August 12, 2026 at 10:18 AM
oncodaily.bsky.social
Prediction on the future of 1st line immunotherapy for NSCLC - Stephen Liu
@stephenvliu.bsky.social

oncodaily.com/blog/237621

#Cancer #FightAgainstCancer #GeorgetownUniversity #ITCD2025 #Ivonescimab #NSCLC #OncoDaily #Oncology #Medicine #Health
Stephen V Liu: Prediction on the future of 1st line immunotherapy for NSCLC - OncoDaily
Stephen V Liu: Prediction on the future of 1st line immunotherapy for NSCLC / cancer, fight against cancer, Georgetown University, Global fight against
oncodaily.com
February 4, 2025 at 4:53 PM
jama.com
Among patients with EGFR-variant nonsquamous #NSCLC whose disease progressed after prior EGFR tyrosine kinase inhibitor therapy, the addition of ivonescimab to #chemotherapy improved overall survival compared with chemotherapy alone.

ja.ma/4a9vgXf
JAMA study on EGFR-variant NSCLC: 322 patients randomized to Ivonescimab+chemo or placebo+chemo. Ivonescimab group's median survival was 16.8 months, significantly better than placebo's 14.1 months (2.7 months difference). Conclusion: Ivonescimab significantly improved overall survival.
June 17, 2026 at 6:11 PM
genomeweb.bsky.social
Akeso, Summit’s Ivonescimab Charges Into Crowded NSCLC Space With Phase III Data
Akeso, Summit’s Ivonescimab Charges Into Crowded NSCLC Space With Phase III Data
Researchers reported data at a recent meeting from two Phase III trials of the PD-1 and VEGF bispecific, one which could open up the US market.
ebx.sh
September 23, 2026 at 8:10 PM
mary-dengyue88.bsky.social
🌟 #Yidafang (Ivonescimab):
Dual #PD-1 & #VEGF Target for #NSCLC! 🌟
💊 Boosts immunity,
blocks tumor growth,
improves survival.

🔗 Learn more: dengyuemed.com/product/ivon...

#HongKongDrugWholesaleDistributor #HongKongDengYueMedicine #Ivonescimab
#Immunotherapy #CancerTreatment
October 14, 2025 at 6:54 AM
vcclibrary.bsky.social
Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses. jitc.bmj.com/content/14/9...
Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses
Thymic carcinoma is a rare, aggressive malignancy with limited treatment options. First-line platinum-based chemotherapy yields response rates below 40%, and immune checkpoint inhibitors have shown in...
jitc.bmj.com
September 25, 2026 at 10:12 AM
natrevdrugdiscov.nature.com
PD1 × VEGF blocking bispecifics for cancer draw big backing
www.nature.com/articles/d41...

Bristol Myers Squibb and Pfizer have both bought in to the PD1 × VEGF bispecific race — chasing Summit and Akeso’s first-in-class candidate ivonescimab
Screenshot of article
June 11, 2025 at 2:59 PM
oncodaily.bsky.social
Morgan Stanley’s Top Oncology Catalysts for 2025
@astrazeneca.bsky.social
@handle.invalid

oncodaily.com/insight/morg...

#AstraZeneca #AZN #BioNTech #BNTX #Cancer #Datopotamab #Deruxtecan #Gilead #GILD #Ivonescimab #Merck #Moderna #OncoDaily #Oncology #Pfizer #Regeneron #SMMT #Medicine #Health
Morgan Stanley’s Top Oncology Catalysts for 2025 - OncoDaily
Morgan Stanley’s Top Oncology Catalysts for 2025 / Antibody drug conjugates, AstraZeneca (AZN), BioNTech (BNTX), cancer, datopotamab deruxtecan, Gilead
oncodaily.com
December 29, 2024 at 9:47 PM
yourdigitalbrain.bsky.social
The drug, also known as AK112 in China and SMT112 outside that market, was developed by the Chinese biopharmaceutical company Akeso , which licensed its rights for the United States, Canada, Europe, and Japan to Summit Therapeutics .
Ivonescimab, PD-1/VEGF bispecific, achieves 80% objective response in triple-negative breast cancer - Sinaptica
What the trial found A phase 2 clinical trial published in Nature Medicine shows that ivonescimab, a bispecific antibody that simultaneously blocks the PD-1 and
sinapti.ca
August 12, 2026 at 10:18 AM